Baxter International Inc. (NYSE:BAX)‘s stock had its “hold” rating restated by equities researchers at Royal Bank Of Canada in a report issued on Tuesday. They currently have a $60.00 target price on the medical instruments supplier’s stock. Royal Bank Of Canada’s target price would suggest a potential downside of 4.61% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. BidaskClub upgraded Baxter International from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 14th. Citigroup Inc. began coverage on Baxter International in a research report on Thursday, August 17th. They set a “neutral” rating and a $63.00 price target on the stock. Zacks Investment Research downgraded Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Cantor Fitzgerald set a $70.00 price target on Baxter International and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, Leerink Swann restated an “outperform” rating and set a $75.00 price target (up previously from $67.00) on shares of Baxter International in a research report on Thursday, July 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $65.42.

Baxter International (NYSE:BAX) opened at 62.90 on Tuesday. Baxter International has a one year low of $43.13 and a one year high of $64.75. The firm has a market cap of $34.27 billion, a PE ratio of 38.17 and a beta of 0.65. The firm has a 50-day moving average price of $62.65 and a 200-day moving average price of $58.83.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.06. The company had revenue of $2.61 billion during the quarter, compared to analyst estimates of $2.59 billion. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The firm’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter last year, the company earned $0.46 earnings per share. On average, equities analysts expect that Baxter International will post $2.39 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Baxter International Inc. (BAX) Stock Rating Reaffirmed by Royal Bank Of Canada” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/baxter-international-inc-bax-stock-rating-reaffirmed-by-royal-bank-of-canada/1609968.html.

In other news, Director Carole J. Shapazian sold 4,020 shares of Baxter International stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.61, for a total value of $247,672.20. Following the transaction, the director now owns 13,868 shares in the company, valued at $854,407.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Giuseppe Accogli sold 12,670 shares of Baxter International stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $60.96, for a total value of $772,363.20. Following the completion of the transaction, the senior vice president now owns 33,286 shares in the company, valued at approximately $2,029,114.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,050 shares of company stock worth $2,158,587. Company insiders own 0.05% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baker Ellis Asset Management LLC purchased a new position in Baxter International during the 2nd quarter valued at about $109,000. Bronfman E.L. Rothschild L.P. increased its holdings in Baxter International by 3.9% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 2,776 shares of the medical instruments supplier’s stock valued at $144,000 after purchasing an additional 103 shares during the period. Acrospire Investment Management LLC increased its holdings in Baxter International by 71.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,402 shares of the medical instruments supplier’s stock valued at $145,000 after purchasing an additional 1,000 shares during the period. Harvest Fund Management Co. Ltd increased its holdings in Baxter International by 8.4% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 2,928 shares of the medical instruments supplier’s stock valued at $177,000 after purchasing an additional 226 shares during the period. Finally, Captrust Financial Advisors purchased a new position in Baxter International during the 2nd quarter valued at about $188,000. Hedge funds and other institutional investors own 83.62% of the company’s stock.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.